BC Week In Review | Sep 26, 2011
Clinical News

Acadra acadesine regulatory update

The European Commission granted Orphan Drug designation for Advancell's Acadra acadesine to treat multiple myeloma (MM). The small molecule that induces apoptosis independent of p53 status is in preclinical testing for MM. Advancell Advanced In...
BC Week In Review | Feb 28, 2011
Clinical News

Acadra acadesine: Phase I/IIa data

An open-label, dose-escalation, European Phase I/IIa trial in 24 patients with relapsed or refractory CLL showed that Acadra was well tolerated and led to reductions in leukemic tumor burden. Additionally, 7 of 9 patients treated...
BC Week In Review | Nov 16, 2009
Company News

Advancell Advanced In Vitro Technologies S.A., BTG deal

BTG returned to Advancell its co-development rights for Acadra acadesine in exchange for an undisclosed potential milestone and royalties. BTG, which gained rights to the nucleoside analogue as part of its 2008 acquisition of Protherics...
BC Week In Review | May 18, 2009
Clinical News

Acadesine: Phase III started

Schering-Plough began the double-blind, placebo-controlled, international Phase III RED-CABG trial to evaluate 42 mg/kg IV acadesine given over 7 hours in 7,500 patients. Administration will begin within 30 minutes of the induction of anesthesia and...
BioCentury | Jan 21, 2008

Ebb & Flow

Despite disappointing product sales, Genentech (NYSE:DNA) managed to beat the Street's 4Q EPS estimate by controlling costs and posting royalty revenues above expectations. Product sales rose only 1% sequentially to $2.35 billion in 4Q07 from...
BC Week In Review | Jan 14, 2008
Clinical News

Acadra acadesine: Phase I/II started

Protherics began an open-label, single- and multiple-ascending dose, European Phase I/II trial in up to 30 relapsed or refractory B-CLL patients. The company is co-developing Acadra with Advancell under a 2006 deal (see BioCentury, Dec....
BC Week In Review | Jul 23, 2007
Company News

PeriCor, Schering-Plough deal

SGP will receive an exclusive worldwide license to develop and commercialize PeriCor's IV acadesine. The adenosine modulator is in Phase III testing to prevent ischemia/reperfusion injury. Financial terms were not disclosed. The deal is expected...
BC Week In Review | Dec 11, 2006
Company News

Protherics, Advanced In Vitro Cell Technologies S.L., Glenveigh Pharmaceuticals LLC, MacroMed deal

PTI acquired drug delivery company MacroMed for £12.7 million ($25.1 million) in stock. The deal gives PTI OncoGel, a sustained-release formulation of paclitaxel that is in Phase IIa testing to treat dysphagia (difficulty swallowing) in...
BC Extra | Dec 8, 2006
Financial News

Protherics raises L38.2 million to fund trio of deals

Cardiovascular, cancer and antibody company Protherics (LSE:PTI; PTIL) raised L38.2 million ($75.6 million) in a placing and open offer of 58.7 million shares at 65p. Nomura and Piper Jaffray were the underwriters. PTI will use...
BC Week In Review | Mar 20, 2006
Clinical News

Acadesine cardiovascular data

Two-year mortality analysis on a subpopulation of 100 patients, who experienced post-reperfusion MI, from the double-blind, placebo-controlled Phase IIIa 1,024 trial in 2,698 patients showed that acadesine reduced the mortality rate by 77% vs. placebo....
Items per page:
1 - 10 of 12